SCHEMBL3934564

SCHEMBL3934564

COc1cnc(-n2ccc(C)n2)c2[nH]cc(C(=O)C(=O)N3CCN(c4c(-c5ccccc5)c(=O)c4=O)CC3)c12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.58
CYP2D6 P10635 3/20 0.58
CYP2C19 P33261 3/20 0.58
CYP3A4 P08684 2/20 0.58
CYP1A2 P05177 2/20 0.58
CYP2C8 P10632 1/20 0.58
CYP2B6 P20813 1/20 0.58
KCNH2 Q12809 1/20 0.58
MGLL Q99685 1/20 0.33
KIT P10721 1/20 0.33
ALOX15 P16050 2/20 0.33
GAA P10253 1/20 0.33
ALOX12 P18054 1/20 0.33
ALDH1A1 P00352 4/20 0.31
TP53 P04637 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
LMNA P02545 1/20 0.31
TRPC6 Q9Y210 1/20 0.31
POLB P06746 1/20 0.31
HSD17B10 Q99714 3/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933354 0.87 CYP3A4 (0.73) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2
SCHEMBL13898870 0.87 CYP2C9 (0.57) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2
SCHEMBL13898964 0.85 CYP2C9 (0.69) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2
SCHEMBL3938306 0.84 CYP2C9 (0.56) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2
SCHEMBL13898961 0.84 CYP2C9 (0.56) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2
SCHEMBL1763161 0.84 CYP2C19 (0.79) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2
SCHEMBL4087963 0.80 CYP2C9 (0.55) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2
SCHEMBL2633381 0.78 CYP2C19 (0.64) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2
SCHEMBL1762943 0.78 CYP2C19 (0.64) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2
SCHEMBL1475113 0.78 CYP3A4 (0.53) CYP2C9CYP2D6CYP2C19CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2013170-B1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2012-06-27 EP disclosed
EP-2013170-B1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL MYERS SQUIBB CO (US) 2012-06-27 EP disclosed
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
US-7501419-B2 4-Squarylpiperazine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2009-03-10 US disclosed
EP-2013170-A1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS Brystol-Myers Squibb Company (US) 2009-01-14 EP disclosed
WO-2007127731-A1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-08 WO disclosed
WO-2007127731-A1 4-SQUARYLPIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-08 WO disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249624-A1 4-Squarylpiperazine Derivatives as Antiviral Agents MAVS, MTAP, SAMHD1 CYP2C9 1983/4885CYP2D6 376/4885CYP2C19 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.